Gotowa bibliografia na temat „DNA Ligase Inhibitors”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „DNA Ligase Inhibitors”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "DNA Ligase Inhibitors"
Alomari, Arqam, Robert Gowland, Callum Southwood, Jak Barrow, Zoe Bentley, Jashel Calvin-Nelson, Alice Kaminski i in. "Identification of Novel Inhibitors of Escherichia coli DNA Ligase (LigA)". Molecules 26, nr 9 (25.04.2021): 2508. http://dx.doi.org/10.3390/molecules26092508.
Pełny tekst źródłaCiarrocchi, Giovanni, Donald G. MacPhee, Les W. Deady i Leann Tilley. "Specific Inhibition of the Eubacterial DNA Ligase by Arylamino Compounds". Antimicrobial Agents and Chemotherapy 43, nr 11 (1.11.1999): 2766–72. http://dx.doi.org/10.1128/aac.43.11.2766.
Pełny tekst źródłaShapiro, Adam B., Ann E. Eakin, Grant K. Walkup i Olga Rivin. "A High-Throughput Fluorescence Resonance Energy Transfer-Based Assay for DNA Ligase". Journal of Biomolecular Screening 16, nr 5 (11.03.2011): 486–93. http://dx.doi.org/10.1177/1087057111398295.
Pełny tekst źródłaHowes, Timothy R. L., Annahita Sallmyr, Rhys Brooks, George E. Greco, Darin E. Jones, Yoshihiro Matsumoto i Alan E. Tomkinson. "Structure-activity relationships among DNA ligase inhibitors: Characterization of a selective uncompetitive DNA ligase I inhibitor". DNA Repair 60 (grudzień 2017): 29–39. http://dx.doi.org/10.1016/j.dnarep.2017.10.002.
Pełny tekst źródłaTAN, Ghee T., Sangkook LEE, Ik-Soo LEE, Jingwen CHEN, Pete LEITNER, Jeffrey M. BESTERMAN, Douglas A. KINGHORN i John M. PEZZUTO. "Natural-product inhibitors of human DNA ligase I". Biochemical Journal 314, nr 3 (15.03.1996): 993–1000. http://dx.doi.org/10.1042/bj3140993.
Pełny tekst źródłaTobin, Lisa A., Aaron P. Rapoport, Ivana Gojo, Maria R. Baer, Alan E. Tomkinson i Feyruz V. Rassool. "DNA Ligase III Alpha and (Poly-ADP) Ribose Polymerase (PARP1) Are Therapeutic Targets in Imatinib-Resistant (IR) Chronic Myeloid Leukemia (CML)." Blood 114, nr 22 (20.11.2009): 853. http://dx.doi.org/10.1182/blood.v114.22.853.853.
Pełny tekst źródłaTomkinson, Alan E., Tasmin Naila i Seema Khattri Bhandari. "Altered DNA ligase activity in human disease". Mutagenesis 35, nr 1 (20.10.2019): 51–60. http://dx.doi.org/10.1093/mutage/gez026.
Pełny tekst źródłaMills, Scott D., Ann E. Eakin, Ed T. Buurman, Joseph V. Newman, Ning Gao, Hoan Huynh, Kenneth D. Johnson i in. "Novel Bacterial NAD+-Dependent DNA Ligase Inhibitors with Broad-Spectrum Activity and Antibacterial EfficacyIn Vivo". Antimicrobial Agents and Chemotherapy 55, nr 3 (28.12.2010): 1088–96. http://dx.doi.org/10.1128/aac.01181-10.
Pełny tekst źródłaHowes, Timothy R. L., Annahita Sallmyr, Rhys Brooks, George E. Greco, Darin E. Jones, Yoshihiro Matsumoto i Alan E. Tomkinson. "Erratum to “Structure-activity relationships among DNA ligase inhibitors; characterization of a selective uncompetitive DNA ligase I inhibitor” [DNA Repair 60C (2017) 29–39]". DNA Repair 61 (styczeń 2018): 99. http://dx.doi.org/10.1016/j.dnarep.2017.12.001.
Pełny tekst źródłaAndo, Kiyohiro, Yusuke Suenaga i Takehiko Kamijo. "DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in MYCN-Amplified Neuroblastoma IMR32 Cells". International Journal of Molecular Sciences 24, nr 10 (19.05.2023): 9012. http://dx.doi.org/10.3390/ijms24109012.
Pełny tekst źródłaRozprawy doktorskie na temat "DNA Ligase Inhibitors"
Papillon, Julie. "Etude structurale et fonctionnelle des complexes de l'ADN gyrase, une ADN topoisomérase bactérienne de type II". Thesis, Strasbourg, 2012. http://www.theses.fr/2012STRAJ127.
Pełny tekst źródłaType II DNA topoisomerases (Topo2A) remodel DNA topology during replication, transcription and chromosome segregation. Most TopoIIA are able to perform ATP-‐dependent DNA relaxation or decatenation but the bacterial DNA gyraseis the sole type II DNA topoisomerase able to introduce negative supercoils. Several biochemical and structural studies haverevealed a highly sophisticated supercoiling catalytic mechanism but despite a wealth of information, the full architectureof Topo2A and the structural basis for DNA supercoiling remain elusive. Due to their physiological roles, topoisomerasesare also important targets for antibiotics targeting the bacterial enzyme but also anti-‐cancer molecules inhibiting the humanprotein. This presented work has combinedboth structural and functional approach to answer the fundamental mechanisticquestions still unveiled and to discover new inhibitors against the emergence of resistant bacterial population
Menchon, Grégory. "Criblage virtuel et fonctionnel sur le complexe XRCC4/ADN ligase IV/Cer-XLF de ligature des cassures double-brin de l'ADN : application en radiosensibilisation tumorale". Thesis, Toulouse 3, 2015. http://www.theses.fr/2015TOU30395.
Pełny tekst źródłaRadiotherapy is a major weapon used against cancer. Radio-induced DNA double strand breaks (DSB) are the main lesions responsible for cell death. Non-homologous end-joining (NHEJ) is a predominant DSB repair mechanism which contributes to cancer cells resistance to radiotherapy. NHEJ is thus a good target for strategies which aim at increasing the radio-sensitivity of tumors. Through in silico screening and biophysical and biochemical assays, our objective was to find specific ligands for the XRCC4/Lig4 and XRCC4/Cer-XLF protein-protein interactions involved in NHEJ. Here, we isolated the first compounds able to prevent their interaction in vitro. These early stage inhibitors are promising tools for cancer therapy with the hope to develop more specific compounds for cellular assays through the 3D structure of the protein/inhibitor complexes
Yu, Deyue. "Identification, caractérisation, et expression de nouveaux gènes chez Arabidopsis thaliana". Université Joseph Fourier (Grenoble), 1994. http://www.theses.fr/1994GRE10102.
Pełny tekst źródłaKim, Jihyun. "The function of CUL-4 ubiquitin ligase complexes in DNA replication and enhancers of cullin-inhibitor CAND-1 in C. elegans". 2009. http://purl.galileo.usg.edu/uga%5Fetd/kim%5Fjihyun%5F200905%5Fphd.
Pełny tekst źródłaFleury, Hubert. "Implication des inhibiteurs de PARP dans le cancer de l’ovaire". Thèse, 2017. http://hdl.handle.net/1866/20221.
Pełny tekst źródłaCzęści książek na temat "DNA Ligase Inhibitors"
Folk, Petr, i James L. Wittliff. "Dephosphorylation in Vitro Inhibits Ligand and DNA Binding Activities of Human Estrogen Receptor". W Tyrosine Phosphorylation/Dephosphorylation and Downstream Signalling, 287–90. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-78247-3_35.
Pełny tekst źródłaMinovski, Nikola, i Marjana Novič. "Integrated in Silico Methods for the Design and Optimization of Novel Drug Candidates". W Oncology, 434–81. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-0549-5.ch016.
Pełny tekst źródłaMinovski, Nikola, i Marjana Novič. "Integrated in Silico Methods for the Design and Optimization of Novel Drug Candidates". W Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment, 269–317. IGI Global, 2015. http://dx.doi.org/10.4018/978-1-4666-8136-1.ch008.
Pełny tekst źródłaGryk, M. R., i O. Jardetzky. "Flexibility and Function of the Excherichia coli trp Represser". W Biological NMR Spectroscopy. Oxford University Press, 1997. http://dx.doi.org/10.1093/oso/9780195094688.003.0011.
Pełny tekst źródłaStreszczenia konferencji na temat "DNA Ligase Inhibitors"
Tseng, Hui-Min, David Shum, Hakim Djaballah i David Scheinberg. "Abstract 3689: Identification of DNA ligase IV inhibitors as possible drug and probe candidates for enhancement of radiation treatment and chemotherapy". W Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3689.
Pełny tekst źródłaLin, Tingting, Zhilian Zhou, Lifeng Zhu, Yandan Fan, Xiaofen Ding i Yingming Sun. "Abstract 3066: DNA ligase IV inhibitor and X-ray exert a synthetic lethal in loss-of-function p53 cells". W Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-3066.
Pełny tekst źródłaRaporty organizacyjne na temat "DNA Ligase Inhibitors"
Altstein, Miriam, i Ronald J. Nachman. Rational Design of Insect Control Agent Prototypes Based on Pyrokinin/PBAN Neuropeptide Antagonists. United States Department of Agriculture, sierpień 2013. http://dx.doi.org/10.32747/2013.7593398.bard.
Pełny tekst źródła